Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease

To evaluate the risk of heart failure and other adverse cardiovascular reactions in Parkinson disease patients treated with non-ergot dopamine agonists, compared to other anti-Parkinson pharmacological interventions, placebo, or no intervention.

This is a protocol.